Volumen: 20 # Number : 3
Publication Date : Septiembre - Diciembre Year: 2016
Chronic myelogenous leukemia and pregnancy
in the era of targeted therapies
Authors: Aguerre L, Moiraghi B
Abstract: The introduction of tyrosine kinase inhibitors (TKI)
in the treatment of chronic myeloid leukemia (CML)
drastically altered the course of the disease.
Most patients achieve survival rates and a quality
of life similar to healthy individuals; thus, common
situations, such as pregnancy, arise. Evidences show
that TKI are not at all harmless in such cases. Severe
malformations in newborn exposed to these drugs
have been reported, then its use is forbidden. Clinical
approach of that situation depends if the disease is
detected during pregnancy, or if a patient already
diagnosed becomes pregnant while on treatment
with a TKI. The best situation is to plan pregnancy
during complete molecular response and to stop
treatment before conception. Alternatives for CML
pregnant patients are the use of α interferon and
leukapheresis; the use of hydroxyurea still remains
controversial. This article reviews the literature
about this condition, mentions worldwide cases and
presents results from 5 pregnancies (2 of them twins)
ocurred while on treatment with TKI registered in
our Center (J.M. Ramos Mejía Hospital, Buenos
Aires- Argentina).
Key words: Chronic myelogenous leukemia,
Pregnancy,
Tyrosine kinase inhibitors.
Pages :
|
